Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENGNNASDAQ:FENCNYSE:RCORNASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENGNenGene$4.20+5.5%$3.95$2.65▼$11.00$214.11M-0.36132,193 shs60,267 shsFENCFennec Pharmaceuticals$7.88-0.6%$6.24$3.96▼$8.56$217.64M0.3296,502 shs54,180 shsRCORRenovacor$3.20$3.07$1.34▼$9.74$55.26M-0.2830,033 shsN/ASLDBSolid Biosciences$3.50-1.1%$3.11$2.41▼$10.37$271.30M2.321.09 million shs1.19 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENGNenGene+2.84%-6.13%+4.19%-31.26%-54.72%FENCFennec Pharmaceuticals-1.25%+0.76%+25.87%+17.83%+16.96%RCORRenovacor0.00%0.00%0.00%0.00%0.00%SLDBSolid Biosciences+10.63%+25.98%-17.87%-33.33%-57.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENGNenGene3.3389 of 5 stars3.55.00.00.02.52.50.6FENCFennec Pharmaceuticals2.3235 of 5 stars3.60.00.00.03.83.30.0RCORRenovacorN/AN/AN/AN/AN/AN/AN/AN/ASLDBSolid Biosciences3.7549 of 5 stars4.61.00.00.02.93.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENGNenGene 3.00Buy$23.29454.42% UpsideFENCFennec Pharmaceuticals 3.25Buy$13.0064.97% UpsideRCORRenovacor 0.00N/AN/AN/ASLDBSolid Biosciences 3.23Buy$14.90325.71% UpsideCurrent Analyst Ratings BreakdownLatest RCOR, SLDB, FENC, and ENGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$16.005/20/2025FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.005/19/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/16/2025SLDBSolid BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.005/16/2025SLDBSolid BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $10.005/16/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$18.00 ➝ $17.005/14/2025FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.005/13/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/29/2025ENGNenGeneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.003/13/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $11.003/11/2025ENGNenGeneMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$37.00 ➝ $34.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENGNenGeneN/AN/AN/AN/A$6.17 per shareN/AFENCFennec Pharmaceuticals$30.91M7.04N/AN/A($0.43) per share-18.33RCORRenovacorN/AN/AN/AN/A$2.47 per shareN/ASLDBSolid Biosciences$8.09M33.54N/AN/A$6.27 per share0.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENGNenGene-$55.14M-$1.52N/AN/AN/AN/A-16.69%-14.27%6/10/2025 (Estimated)FENCFennec Pharmaceuticals-$16.05M-$0.51N/AN/AN/A-2.30%-53.38%-2.08%8/12/2025 (Estimated)RCORRenovacor-$14.10M-$0.73N/AN/AN/AN/A-62.88%-48.90%N/ASLDBSolid Biosciences-$96.01M-$2.99N/AN/AN/AN/A-58.75%-47.84%8/12/2025 (Estimated)Latest RCOR, SLDB, FENC, and ENGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/10/2025Q2 2025ENGNenGene-$0.4768N/AN/AN/AN/AN/A5/15/2025Q1 2025SLDBSolid Biosciences-$0.53-$0.59-$0.06-$0.59N/AN/A5/13/2025Q1 2025FENCFennec Pharmaceuticals-$0.12-$0.04+$0.08-$0.04$8.18 million$8.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENGNenGene$1.5837.64%N/AN/A N/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENGNenGene0.0816.8716.87FENCFennec PharmaceuticalsN/A7.807.64RCORRenovacorN/A6.606.60SLDBSolid BiosciencesN/A7.857.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENGNenGene64.16%FENCFennec Pharmaceuticals55.51%RCORRenovacor45.84%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipENGNenGene10.40%FENCFennec Pharmaceuticals11.76%RCORRenovacor14.40%SLDBSolid Biosciences1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENGNenGene3150.98 million38.16 millionN/AFENCFennec PharmaceuticalsN/A27.62 million24.54 millionOptionableRCORRenovacor1917.27 million14.78 millionNot OptionableSLDBSolid Biosciences10077.52 million35.05 millionOptionableRCOR, SLDB, FENC, and ENGN HeadlinesRecent News About These CompaniesSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3 at 8:00 AM | globenewswire.comSolid Biosciences Inc. (NASDAQ:SLDB) Short Interest UpdateJune 3 at 1:34 AM | marketbeat.comMillennium Management LLC Sells 397,321 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)June 1 at 3:43 AM | marketbeat.comSolid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthroughMay 28, 2025 | investing.comSolid Biosciences to Participate at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by BrokeragesMay 28, 2025 | marketbeat.comResearch Analysts Set Expectations for SLDB FY2025 EarningsMay 27, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Earns "Overweight" Rating from Cantor FitzgeraldMay 24, 2025 | marketbeat.comChardan Capital Has Lowered Expectations for Solid Biosciences (NASDAQ:SLDB) Stock PriceMay 21, 2025 | marketbeat.comQ1 Earnings Forecast for SLDB Issued By William BlairMay 21, 2025 | marketbeat.comTruist maintains buy on Solid Biosciences stock, price target at $16May 18, 2025 | investing.comDimensional Fund Advisors LP Purchases 192,714 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)May 18, 2025 | marketbeat.comWhen Might Solid Biosciences Run Out Of Money?May 17, 2025 | finance.yahoo.comSolid Biosciences (NASDAQ:SLDB) Upgraded by Cantor Fitzgerald to "Strong-Buy" RatingMay 17, 2025 | marketbeat.comSolid Biosciences Inc.: Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 16, 2025 | finanznachrichten.deSolid Biosciences (SLDB) Expected to Announce Earnings on WednesdayMay 16, 2025 | marketbeat.comSolid Biosciences files for $400M mixed securities shelf offeringMay 16, 2025 | msn.comSolid Biosciences Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 15, 2025 | globenewswire.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Buy" by BrokeragesMay 4, 2025 | marketbeat.comWhy Solid Biosciences Inc.’s (SLDB) Stock Is Up 10.82%May 3, 2025 | aaii.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCOR, SLDB, FENC, and ENGN Company DescriptionsenGene NASDAQ:ENGN$4.20 +0.22 (+5.53%) Closing price 04:00 PM EasternExtended Trading$4.18 -0.02 (-0.50%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Fennec Pharmaceuticals NASDAQ:FENC$7.88 -0.05 (-0.63%) Closing price 04:00 PM EasternExtended Trading$7.87 -0.01 (-0.13%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Renovacor NYSE:RCORRenovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.Solid Biosciences NASDAQ:SLDB$3.50 -0.04 (-1.13%) Closing price 04:00 PM EasternExtended Trading$3.52 +0.02 (+0.43%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
